| ［1］ |
中国抗癌协会，中国抗癌协会大肠癌专业委员会. 中国恶性肿瘤整合诊治指南-直肠癌部分［J/OL］. 中华结直肠疾病电子杂志，2022，11（2）：89-103.China Anti-Cancer Association，Colorectal Cancer Professional Committee，Chinese Anti-Cancer Association. CACA guidelines for holistic integrative management of cancer-Rectal cancer［J/OL］. Chin J Colorec Dis （Electronic Edition），2022，11（2）：89-103.
|
| ［2］ |
中国抗癌协会，中国抗癌协会大肠癌专业委员会. 中国肿瘤整合诊治指南. 结直肠癌、肛管癌. ［M］. 天津：天津科学技术出版社，2022.
|
| ［3］ |
Wang G，Fan D，Gu J，et al. CACA guidelines for holistic integrative management of rectal cancer［J］. Holistic Integrative Oncology，2023，2（1）：1-31.
|
| ［4］ |
Han B，Zheng R，Zeng H，et al. Cancer incidence and mortality in China，2022［J］. J Natl Cancer Cent，2024，4（1）：47-53.
|
| ［5］ |
Zheng RS，Zhang SW，Zeng HM，et al. Cancer incidence and mortality in China，2016［J］. J Natl Cancer Cent，2022，2（1）：1-9.
|
| ［6］ |
Chen XP，Wang JP，Zao JZ. Surgery［M］. 9th，Beijing：People's Medical Publishing House，2018.
|
| ［7］ |
Rock CL，Doyle C，Demark-Wahnefried W，et al. Nutrition and physical activity guidelines for cancer survivors［J］. CA Cancer J Clin，2012，62（4）：243-274.
|
| ［8］ |
李鹏，王拥军，陈光勇，等. 中国早期结直肠癌及癌前病变筛查与诊治共识［J］. 中国实用内科杂志，2015，35（3）：211-227.
|
| ［9］ |
Ma QL，Ma XY，Yu LL，et al. Age-specific detection rates of colorectal neoplasms by colonoscopic screening in high-incidence rural area［J］.Chinese Journal of Oncology，2013，35（2）：154-157.
|
| ［10］ |
Davidson KW，Barry MJ，Mangione CM，et al. Screening for colorectal cancer：us preventive services task force recommendation statement［J］. JAMA，2021，325（19）：1965-1977.
|
| ［11］ |
Cai G，Cai M，Feng Z，et al. A Multilocus blood-based assay targeting circulating tumor DNA methylation enables early detection and early relapse prediction of colorectal cancer［J］. Gastroenterology，2021，161（6）：2053-2056.e2.
|
| ［12］ |
国家癌症中心中国结直肠癌筛查与早诊早治指南制定专家组. 中国结直肠癌筛查与早诊早治指南（2020，北京）［J］. 中华肿瘤杂志，2021，43（1）：16-38.National Cancer Center，Expert Group of the Development of China Guideline for the Screening，Early Detection and Early Treatment of Colorectal Cancer. China guideline for the screening，early detection and early treatment of colorectal cancer （2020，Beijing）［J］. Chin J Oncol，2021，43（1）：16-38.
|
| ［13］ |
Early Diagnosis and Treatment Group，the Oncology Committee of Chinese Medical Association. Expert consensus on early diagnosis and treatment of colorectal cancer in China［J］. National Medical Journal of China，2020，100（22）：1691-1698.
|
| ［14］ |
Hampel H，Frankel WL，Martin E，et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer［J］. J Clin Oncol，2008，26（35）：5783-5788.
|
| ［15］ |
Yuan Y，Zhang SZ，Zheng S，et al. Implementation scheme of screening standard for hereditary colorectal cancer in China［J］. Chinese Journal of Oncology，2004，26（3）：191-192.
|
| ［16］ |
Committee of Colorectal Cancer，Chinses Society of Clinical Oncology. Genetics Group of the Committee of Colorectal Cancer，China Anti-cancer Association. Genetics Committee of the Committee of Colorectal Cancer，Chinese Medical Doctor Association. Consensus on detection of microsatellite instability in colorectal cancer and other related solid tumors in China ［J］. Chinese Journal of Oncology，2019，4（10）：734-741.
|
| ［17］ |
Sieber OM，Segditsas S，Knudsen AL，et al. Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly but depend on the site of the germline mutation［J］. Gut，2006，55（10）：1440-1448.
|
| ［18］ |
Yang M，Zhu L，Zhu L，et al. Role of a rare variant in APC gene promoter 1B region in classic familial adenomatous polyposis［J］.Digestion，2021，102（4）：527-533.
|
| ［19］ |
Wang Z，Zhao X，Gao C，et al. Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment［J］.J Immunother Cancer，2020，8（2）：e001297.
|
| ［20］ |
樊代明. 整合肿瘤学·临床卷［M］. 北京：科学出版社，2021.
|
| ［21］ |
樊代明. 整合肿瘤学·基础卷［M］. 西安：世界图书出版西安有限公司，2021.
|
| ［22］ |
Tanaka S，Kashida H，Saito Y，et al. Japan Gastroenterological Endoscopy Society guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection［J］. Dig Endosc，2020，32（2）：219-239.
|
| ［23］ |
Saito Y，Fukuzawa M，Matsuda T，et al. Clinical outcome of endoscopic submucosal dissection versus endoscopic mucosal resection of large colorectal tumors as determined by curative resection［J］. Surg Endosc，2010，24（2）：343-352.
|
| ［24］ |
Pathologic Collaborative Croup，Association of Digestive Endoscopy of Chinese Medical Association. Consensus on biopsy and pathologic examination of digestive endoscopy in China （Draft） ［J］. Chinese Journal of Digestive Endoscopy，2014，31（9）：481-485.
|
| ［25］ |
Wang XS，Li ZF，Su M. An introduction to oncology［M］. 2nd，Beijing：People's Medical Publishing House，2021.
|
| ［26］ |
Xu L，Su X，He Z，et al. Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer （RELARC）：a randomised，controlled，phase 3，superiority trial［J］. Lancet Oncol，2021，22（3）：391-401.
|
| ［27］ |
Guan X，Hu X，Jiang Z，et al. Short-term and oncological outcomes of natural orifice specimen extraction surgery （NOSES） for colorectal cancer in China：a national database study of 5055 patients［J］. Sci Bull（Beijing），2022，67（13）：1331-1334.
|
| ［28］ |
中国NOSES联盟，中国医师协会结直肠肿瘤专业委员会NOSES专委会. 结直肠肿瘤经自然腔道取标本手术专家共识（2019版）［J/CD］. 中华结直肠疾病电子杂志，2019，8（4）：336-342.China NOSES Alliance，Professional Committee of Natural Orifice Specimen Extraction Surgery，Colorectal Cancer Committee of Chinese Medical Doctor Association. Expert consensus of natural orifice specimen extraction surgery in colorectal neoplasm （2019）［J/CD］. Chin J Colorec Dis （Electronic Edition），2019，8（4）：336-342.
|
| ［29］ |
Van Hooft JE，Van Halsema EE，Vanbiervliet G，et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer：European society of gastrointestinal endoscopy （ESGE） clinical guideline［J］.Endoscopy，2014，46（11）：990-1053.
|
| ［30］ |
Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced，operable colon cancer：the pilot phase of a randomised controlled trial［J］. Lancet Oncol，2012，13（11）：1152-1160.
|
| ［31］ |
Qiu B，Ding PR，Cai L，et al. Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer［J］. Chin J Cancer，2016，35（1）：65.
|
| ［32］ |
Hu H，Kang L，Zhang J，et al. Neoadjuvant PD-1 blockade with toripalimab，with or without celecoxib，in mismatch repair-deficient or microsatellite instability-high，locally advanced，colorectal cancer（PICC）：a single-centre，parallel-group，non-comparative，randomised，phase 2 trial［J］. Lancet Gastroenterol Hepatol，2022，7（1）：38-48.
|
| ［33］ |
Chalabi M，Verschoor YL，Berg JVD，et al. LBA7 neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer：The NICHE-2 study［J］. Annals of Oncology，2022，Ann Oncol，2022，33（l）. s1389：33.
|
| ［34］ |
Gao P，Huang XZ，Song YX，et al. Impact of timing of adjuvant chemotherapy on survival in stage Ⅲ colon cancer：a population-based study［J］. BMC Cancer，2018，18（1）：234.
|
| ［35］ |
Pagès F，André T，Taieb J，et al. Corrigendum to prognostic and predictive value of the immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGEGERCOR cohort study：annals of oncology 2020，Volume 31：921-929［J］. Ann Oncol，2020，31（9）：1276.
|
| ［36］ |
André T，Boni C，Mounedji-Boudiaf L，et al. Oxaliplatin，fluorouracil，and leucovorin as adjuvant treatment for colon cancer［J］. N Engl J Med，2004，350（23）：2343-2351.
|
| ［37］ |
Tie J，Cohen JD，Lahouel K，et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer［J］. N Engl J Med，2022，386（24）：2261-2272.
|
| ［38］ |
Roth AD，Delorenzi M，Tejpar S，et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer［J］. J Natl Cancer Inst，2012，104（21）：1635-1646.
|
| ［39］ |
Wells KO，Hawkins AT，Krishnamurthy DM，et al. Omission of adjuvant chemotherapy is associated with increased mortality in patients with T3N0 colon cancer with inadequate lymph node harvest［J］. Dis Colon Rectum，2017，60（1）：15-21.
|
| ［40］ |
Ribic CM，Sargent DJ，Moore MJ，et al. Tumor microsatelliteinstability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer［J］. N Engl J Med，2003，349（3）：247-257.
|
| ［41］ |
Sargent DJ，Marsoni S，Monges G，et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer［J］. J Clin Oncol，2010，28（20）：3219-3226.
|
| ［42］ |
Sinicrope FA，Foster NR，Thibodeau SN，et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy［J］. J Natl Cancer Inst，2011，103（11）：863-875.
|
| ［43］ |
Tejpar S，Saridaki Z，Delorenzi M，et al. Microsatellite instability，prognosis and drug sensitivity of stage II and III colorectal cancer：more complexity to the puzzle［J］. J Natl Cancer Inst，2011，103（11）：841-844.
|
| ［44］ |
Quah HM，Chou JF，Gonen M，et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy［J］. Dis Colon Rectum，2008，51（5）：503-507.
|
| ［45］ |
Schmoll HJ，Tabernero J，Maroun J，et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer：final results of the NO16968 randomized controlled phase III trial［J］. J Clin Oncol，2015，33（32）：3733-3740.
|
| ［46］ |
André T，Boni C，Navarro M，et al. Improved overall survival with oxaliplatin，fluorouracil，and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial［J］. J Clin Oncol，2009，27（19）：3109-3116.
|
| ［47］ |
Grothey A，Sobrero AF，Shields AF，et al. Duration of adjuvant chemotherapy for stage III colon cancer［J］. N Engl J Med，2018，378（13）：1177-1188.
|
| ［48］ |
Van Cutsem E，Labianca R，Bodoky G，et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer：PETACC-3［J］. J Clin Oncol，2009，27（19）：3117-3125.
|
| ［49］ |
Alberts SR，Sargent DJ，Nair S，et al. Effect of oxaliplatin，fluorouracil，and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer：a randomized trial［J］. JAMA，2012，307（13）：1383-1393.
|
| ［50］ |
Allegra CJ，Yothers G，O'connell MJ，et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon：results of NSABP protocol C-08［J］. J Clin Oncol，2011，29（1）：11-16.
|
| ［51］ |
De Gramont A，Van Cutsem E，Schmoll HJ，et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer（AVANT）：a phase 3 randomised controlled trial［J］. Lancet Oncol，2012，13（12）：1225-1233.
|
| ［52］ |
Fong Y，Fortner J，Sun RL，et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer：analysis of 1001 consecutive cases［J］. Ann Surg，1999，230（3）：309-318； discussion 318-321.
|
| ［53］ |
Ayez N，Van Der Stok EP，Grünhagen DJ，et al. The use of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases：clinical risk score as possible discriminator［J］. Eur J Surg Oncol，2015，41（7）：859-867.
|
| ［54］ |
Nordlinger B，Sorbye H，Glimelius B，et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer （EORTC 40983）：long-term results of a randomised，controlled，phase 3 trial［J］. Lancet Oncol，2013，14（12）：1208-1215.
|
| ［55］ |
Bridgewater JA，Pugh SA，Maishman T，et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis （New EPOC）：long-term results of a multicentre，randomised，controlled，phase 3 trial［J］. Lancet Oncol，2020，21（3）：398-411.
|
| ［56］ |
Van Cutsem E，Cervantes A，Adam R，et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer［J］. Ann Oncol，2016，27（8）：1386-1422.
|
| ［57］ |
中国临床肿瘤学会指南工作委员会. 2024 CSCO结直肠癌指南［M］. 北京：人民卫生出版社，2024.
|
| ［58］ |
Chinese College of Surgeons，Chinese Medical Doctor Association.Chinese Society of Gastrointestinal Surgery，Chinese Society of Surgery of Chinese Medical Association. Chinese Society of Colorectal Surgery，Chinese society of surgery of chinese medical association，etc. China guideline for diagnosis and comprehensive reatment of colorectal liver metastases （2020 Version） ［J］. Chin J Gastrointest Surg，2021，24（1）：1-13.
|
| ［59］ |
Adam R. Chemotherapy and surgery：new perspectives on the treatment of unresectable liver metastases［J］. Ann Oncol，2003，14（Suppl. 2）：ii13-16.
|
| ［60］ |
Aloia T，Sebagh M，Plasse M，et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases［J］. J Clin Oncol，2006，24（31）：4983-4990.
|
| ［61］ |
Fernandez FG，Ritter J，Goodwin JW，et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases［J］. J Am Coll Surg，2005，200（6）：845-853.
|
| ［62］ |
Adam R，Bhangui P，Poston G，et al. Is perioperative chemotherapy useful for solitary，metachronous，colorectal liver metastases？［J］. Ann Surg，2010，252（5）：774-787.
|
| ［63］ |
Colucci G，Gebbia V，Paoletti G，et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer：a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale［J］. J Clin Oncol，2005，23（22）：4866-4875.
|
| ［64］ |
Alberts SR，Horvath WL，Sternfeld WC，et al. Oxaliplatin，fluorouracil，and leucovorin for patients with unresectable liver-only metastases from colorectal cancer：a North Central Cancer Treatment Group phase II study［J］. J Clin Oncol，2005，23（36）：9243-9249.
|
| ［65］ |
Souglakos J，Androulakis N，Syrigos K，et al. FOLFOXIRI （folinic acid，5-fluorouracil，oxaliplatin and irinotecan） vs FOLFIRI （folinic acid，5-fluorouracil and irinotecan） as first-line treatment in metastatic colorectal cancer （MCC）：a multicentre randomised phase III trial from the Hellenic Oncology Research Group （HORG）［J］. Br J Cancer，2006，94（6）：798-805.
|
| ［66］ |
Ye LC，Liu TS，Ren L，et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases［J］. J Clin Oncol，2013，31（16）：1931-1938.
|
| ［67］ |
Tomasello G，Petrelli F，Ghidini M，et al. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer：a systematic review and pooled analysis［J］. JAMA Oncol，2017，3（7）：e170278.
|
| ［68］ |
Ye L C，Wei Y，Zhu DX，et al. Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab［J］. J Gastroenterol Hepatol，2015，30（4）：674-679.
|
| ［69］ |
Arnold D，Lueza B，Douillard JY，et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials［J］. Ann Oncol，2017，28（8）：1713-1729.
|
| ［70］ |
Tang W，Ren L，Liu T，et al. Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases：the BECOME randomized controlled trial［J］. J Clin Oncol，2020，38（27）：3175-3184.
|
| ［71］ |
Cremolini C，Loupakis F，Antoniotti C，et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer：updated overall survival and molecular subgroup analyses of the open-label，phase 3 TRIBE study［J］. Lancet Oncol，2015，16（13）：1306-1315.
|
| ［72］ |
Stein A，Atanackovic D，Hildebrandt B，et al. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer［J］. Br J Cancer，2015，113（6）：872-877.
|
| ［73］ |
Margonis GA，Buettner S，Andreatos N，et al. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer［J］. JAMA Surg，2018，153（7）：e180996.
|
| ［74］ |
Haddad R，Ogilvie RT，Croitoru M，et al. Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases［J］. Ann Surg Oncol，2004，11（11）：977-982.
|
| ［75］ |
André T，Shiu KK，Kim TW，et al. Pembrolizumab in microsatelliteinstability-high advanced colorectal cancer［J］. N Engl J Med，2020，383（23）：2207-2218.
|
| ［76］ |
Faron M，Pignon JP，Malka D，et al. Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases？ A pooled analysis of individual data from four randomised trials［J］. Eur J Cancer，2015，51（2）：166-176.
|
| ［77］ |
Tarantino I，Warschkow R，Güller U. Palliative primary tumor resection in patients with metastatic colorectal cancer：for whom and when？［J］. Ann Surg，2017，265（4）：e59-e60.
|
| ［78］ |
Moritani K，Kanemitsu Y，Shida D，et al. A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage Ⅳ colorectal cancer：JCOG1007（iPACS study）［J］. Jpn J Clin Oncol，2020，50（1）：89-93.
|
| ［79］ |
Hu CY，Bailey CE，You YN，et al. Time trend analysis of primary tumor resection for stage IV colorectal cancer：less surgery，improved survival［J］. JAMA Surg，2015，150（3）：245-251.
|
| ［80］ |
Tournigand C，André T，Achille E，et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer：a randomized GERCOR study［J］. J Clin Oncol，2004，22（2）：229-237.
|
| ［81］ |
Saltz LB，Clarke S，Díaz-Rubio E，et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer：a randomized phase III study［J］. J Clin Oncol，2008，26（12）：2013-2019.
|
| ［82］ |
Falcone A，Ricci S，Brunetti I，et al. Phase III trial of infusional fluorouracil，leucovorin，oxaliplatin，and irinotecan （FOLFOXIRI）compared with infusional fluorouracil，leucovorin，and irinotecan（FOLFIRI） as first-line treatment for metastatic colorectal cancer：the Gruppo Oncologico Nord Ovest［J］. J Clin Oncol，2007，25（13）：1670-1676.
|
| ［83］ |
Heinemann V，Von Weikersthal LF，Decker T，et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer （FIRE-3）：a randomised，open-label，phase 3 trial［J］. Lancet Oncol，2014，15（10）：1065-1075.
|
| ［84］ |
Venook AP，Niedzwiecki D，Lenz HJ，et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer：a randomized clinical trial［J］. JAMA，2017，317（23）：2392-2401.
|
| ［85］ |
Cremolini C，Antoniotti C，Rossini D，et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer （TRIBE2）：a multicentre，open-label，phase 3，randomised，controlled trial［J］.Lancet Oncol，2020，21（4）：497-507.
|
| ［86］ |
Le DT，Uram JN，Wang H，et al. PD-1 blockade in tumors with mismatch-repair deficiency［J］. N Engl J Med，2015，372（26）：2509-2520.
|
| ［87］ |
Michael J. Overman HL，Thierry A，et al. Nivolumab （NIVO） ±ipilimumab （IPI） in patients （pts） with microsatellite instability-high/mismatch repair-deficient （MSI-H/dMMR） metastatic colorectal cancer （mCRC）：five-year follow-up from CheckMate 142［J］. Journal of Clinical Oncology，2022，40（suppl. 16）：40.
|
| ［88］ |
Xu RH，Shen L，Li J，et al. Expert consensus on maintenance treatment for metastatic colorectal cancer in China［J］. Chin J Cancer，2016，35：13.
|
| ［89］ |
Chibaudel B，Maindrault-Goebel F，Lledo G，et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer？ The GERCOR OPTIMOX2 Study［J］. J Clin Oncol，2009，27（34）：5727-5733.
|
| ［90］ |
Luo HY，Li YH，Wang W，et al. Single-agent capecitabine as maintenance therapy after induction of XELOX （or FOLFOX） in firstline treatment of metastatic colorectal cancer：randomized clinical trial of efficacy and safety［J］. Ann Oncol，2016，27（6）：1074-1081.
|
| ［91］ |
Quidde J，Hegewisch-Becker S，Graeven U，et al. Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment：a preplanned analysis of the phase III AIO KRK 0207 trial［J］. Ann Oncol，2016，27（12）：2203-2210.
|
| ［92］ |
Cunningham D，Lang I，Marcuello E，et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer （AVEX）：an openlabel，randomised phase 3 trial［J］. Lancet Oncol，2013，14（11）：1077-1085.
|
| ［93］ |
Van Cutsem E，Danielewicz I，Saunders MP，et al. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy：the randomized TASCO1 study［J］. Ann Oncol，2020，31（9）：1160-1168.
|
| ［94］ |
Cunningham D，Humblet Y，Siena S，et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer［J］. N Engl J Med，2004，351（4）：337-345.
|
| ［95］ |
Xu RH，Muro K，Morita S，et al. Modified XELIRI （capecitabine plus irinotecan） versus FOLFIRI （leucovorin，fluorouracil，and irinotecan），both either with or without bevacizumab，as second-line therapy for metastatic colorectal cancer （AXEPT）：a multicentre，open-label，randomised，non-inferiority，phase 3 trial［J］. Lancet Oncol，2018，19（5）：660-671.
|
| ［96］ |
Thomas RJ，Williams M，Garcia-Vargas J. Lessons learned from raltitrexed--quality assurance，patient education and intensive supportive drugs to optimise tolerability［J］. Clin Oncol （R Coll Radiol），2003，15（5）：227-232.
|
| ［97］ |
王佳蕾，郑磊贞，胡春宏，等. 雷替曲塞或氟尿嘧啶/亚叶酸钙联合奥沙利铂治疗局部晚期或复发转移性结直肠癌的随机对照多中心Ⅲ期临床试验［J］. 临床肿瘤学杂志，2012，17（1）：6-11.
|
| ［98］ |
Bennouna J，Sastre J，Arnold D，et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer （ML18147）：a randomised phase 3 trial［J］. Lancet Oncol，2013，14（1）：29-37.
|
| ［99］ |
Van Cutsem E，Tabernero J，Lakomy R，et al. Addition of aflibercept to fluorouracil，leucovorin，and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen［J］. J Clin Oncol，2012，30（28）：3499-3506.
|
| ［100］ |
Bennouna J，Hiret S，Bertaut A，et al. Continuation of bevacizumab vs cetuximab plus chemotherapy after first progression in KRAS wildtype metastatic colorectal cancer：The UNICANCER PRODIGE18 randomized clinical trial［J］. JAMA Oncol，2019，5（1）：83-90.
|
| ［101］ |
Innocenti F，Ou FS，Qu X，et al. Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome［J］. J Clin Oncol，2019，37（14）：1217-1227.
|
| ［102］ |
Kopetz S，Guthrie KA，Morris VK，et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAFmutant metastatic colorectal cancer （SWOG S1406）［J］.2021，39（4）：285-294.
|
| ［103］ |
Corcoran RB，Atreya CE，Falchook GS，et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer［J］. J Clin Oncol，2015，33（34）：4023-4031.
|
| ［104］ |
Corcoran RB，André T，Atreya CE，et al. Combined BRAF，EGFR，and MEK inhibition in patients with BRAF（V600E）-mutant colorectal cancer［J］. Cancer Discov，2018，8（4）：428-443.
|
| ［105］ |
Overman MJ，Lonardi S，Wong KYM，et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer［J］. J Clin Oncol，2018，36（8）：773-779.
|
| ［106］ |
Le DT，Kim TW，Van Cutsem E，et al. Phase II Open-label study of pembrolizumab in treatment-refractory，microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer：KEYNOTE-164［J］. J Clin Oncol，2020，38（1）：11-19.
|
| ［107］ |
Wang F，Zhao Q，Wang YN，et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types［J］. JAMA Oncol，2019，5（10）：1504-1506.
|
| ［108］ |
Li J，Qin S，Xu R，et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer （CONCUR）：a randomised，double-blind，placebo-controlled，phase 3 trial［J］. Lancet Oncol，2015，16（6）：619-629.
|
| ［109］ |
Li J，Qin S，Xu RH，et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer：the FRESCO randomized clinical trial［J］. JAMA，2018，319（24）：2486-2496.
|
| ［110］ |
Xu J，Kim TW，Shen L，et al. Results of a randomized，double-blind，placebo-controlled，phase III trial of trifluridine/tipiracil （TAS-102）monotherapy in asian patients with previously treated metastatic colorectal cancer：the TERRA study［J］. J Clin Oncol，2018，36（4）：350-358.
|
| ［111］ |
Sartore-Bianchi A，Trusolino L，Martino C，et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory，KRAS codon 12/13 wild-type，HER2-positive metastatic colorectal cancer（HERACLES）：a proof-of-concept，multicentre，open-label，phase 2 trial［J］. Lancet Oncol，2016，17（6）：738-746.
|
| ［112］ |
Meric-Bernstam F，Hurwitz H，Raghav KPS，et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer（MyPathway）：an updated report from a multicentre，open-label，phase 2a，multiple basket study［J］. Lancet Oncol，2019，20（4）：518-530.
|
| ［113］ |
Cremolini C，Rossini D，Dell'aquila E，et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan：a phase 2 single-arm clinical trial［J］. JAMA Oncol，2019，5（3）：343-350.
|
| ［114］ |
Cocco E，Scaltriti M，Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy［J］. Nat Rev Clin Oncol，2018，15（12）：731-747.
|
| ［115］ |
中国医师协会外科医师分会多学科综合治疗专业委员会，中国抗癌协会大肠癌专业委员会. 结直肠癌肺转移多学科综合治疗专家共识（2018版）［J］. 中国实用外科杂志，2018，38（12）：1325-1338.
|
| ［116］ |
Ceelen WP，Flessner MF. Intraperitoneal therapy for peritoneal tumors：biophysics and clinical evidence［J］. Nat Rev Clin Oncol，2010，7（2）：108-115.
|
| ［117］ |
Koppe MJ，Boerman OC，Oyen WJ，et al. Peritoneal carcinomatosis of colorectal origin：incidence and current treatment strategies［J］. Ann Surg，2006，243（2）：212-222.
|
| ［118］ |
Jayne DG，Fook S，Loi C，et al. Peritoneal carcinomatosis from colorectal cancer［J］. Br J Surg，2002，89（12）：1545-1550.
|
| ［119］ |
Passot G，Dumont F，Goéré D，et al. Multicentre study of laparoscopic or open assessment of the peritoneal cancer index （BIG-RENAPE）［J］.Br J Surg，2018，105（6）：663-667.
|
| ［120］ |
Elias D，Mariani A，Cloutier AS，et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin［J］. Eur J Surg Oncol，2014，40（11）：1467-1473.
|
| ［121］ |
Ceelen WP，Påhlman L，Mahteme H. Pharmacodynamic aspects of intraperitoneal cytotoxic therapy［J］. Cancer Treat Res，2007，134：195-214.
|
| ［122］ |
Sugarbaker PH. Surgical treatment of peritoneal carcinomatosis：1988 Du Pont lecture［J］. Can J Surg，1989，32（3）：164-170.
|
| ［123］ |
Zhou HY，Yuan M，Min WP，et al. Meta-analysis of implanting sustained-releasing 5-fluorouracil in colorectal cancer surgery［J］.China Pharmacy，2017，28（3）：355-359.
|
| ［124］ |
陈佳楠，王征，张阿龙，等. 雷替曲塞用于结直肠癌术中腹腔灌注化疗的近期安全性评估［J/CD］. 中华结直肠疾病电子杂志，2019，8（3）：241-245.Chen JN，Wang Z，Hang AL，et al. Short-term safety evaluation of intraperitoneal chemotherapy with raltitrexed for colorectal cancer［J］.Chinese Journal of Colorectal Diseases （Electronic Edition），2019，8（3）：241-245.
|
| ［125］ |
中国医师协会结直肠肿瘤专业委员会腹膜肿瘤专业委员会. 结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识（Ⅴ2019）［J/CD］.中华结直肠疾病电子杂志，2019，8 （4）：329-335.Professional Committee of Peritoneal Neoplasms，Committee of Colorectal Cancer of Chinese Medical Doctor Association. Chinese expert consensus for prophylactic and therapeutic intraperitoneal medication for peritoneal metastases from colorectal cancer （V 2019）［J/CD］. Chin J Colorec Dis （Electronic Edition），2019，8（4）：329-335.
|
| ［126］ |
苏昊，周海涛，王锡山，等. 洛铂用于结直肠癌术中腹腔灌洗化疗的近期疗效分析［J/CD］. 中华结直肠疾病电子杂志，2018，7（2）：125-129.Su H，Zhou HT，Wang XS，et al. The short-term effect analysis of intraoperative intraperitoneal perfusion chemotherapy with Lobaplatin for colorectal cancer［J/CD］. Chin J Colorec Dis （Electronic Edition），2018，7（2）：125-129.
|
| ［127］ |
中国医师协会结直肠肿瘤专业委员会. 中国结直肠癌卵巢转移诊疗专家共识（2020版）［J/CD］. 中华结直肠疾病电子杂志，2020，9（2）：115-121.Colorectal Cancer Committee of Chinese Medical Doctor Association.Chinese experts consensus on the management of ovarian metastases from colorectal cancer （2020 version） ［J/CD］. Chin J Colorec Dis（Electronic Edition），2020，9（2）：115-121.
|
| ［128］ |
中国医师协会结直肠肿瘤专业委员会. 中国结直肠癌骨转移多学科综合治疗专家共识（2020版）［J/CD］. 中华结直肠疾病电子杂志，2020，9（3）：217-221.The Chinese Society of Colorectal Cancer. Chinese expert consensus on multidisciplinary treatment of bone metastasis from colorectal cancer （2020 version） ［J/CD］. Chin J Colorec Dis （Electronic Edition），2020，9（3）：217-221.
|
| ［129］ |
中国医师协会结直肠肿瘤专业委员会. 中国结直肠癌脑转移多学科综合治疗专家共识（2020版）［J/CD］. 中华结直肠疾病电子杂志，2020，9（2）：109-114.Committee of Colorectal Cancer，Chinese Medical Doctor Association.Chinese expert consensus on multidisciplinary treatment of brain metastases from colorectal cancer （2020 version） ［J/CD］. Chin J Colorec Dis （Electronic Edition），2020，9（2）：109-114.
|
| ［130］ |
National Health Commission of the People's Republic of China.Chinese guidelines of diagnosis and treatment of colorectal cancer 2020［J］. Chinese Journal of Surgery，2020，（8）：561-585.
|
| ［131］ |
Huang LZ. Oncology of integrated traditional Chinese and Western medicine［M］. Beijing：China Press of Traditional Chinese Medicine，2020.
|
| ［132］ |
Wang XM. Practical oncology of integrated traditional chinese and western medicine［M］. Beijing：China Press of Traditional Chinese Medicine，2014.
|
| ［133］ |
Zhou DH. Traditional chinese medicine oncology［M］. Beijing：China Press of Traditional Chinese Medicine，2011.
|
| ［134］ |
程海波，贾立群. 中西医结合肿瘤学［M］. 北京：中国中医药出版社，2023.
|
| ［135］ |
许云，费宇彤，陈楠，等. 结直肠癌化疗期中医诊疗指南［J］. 北京中医药，2023，42（4）：348-350.Xu Y，Fei YT，Chen N，et al. Guidelines for TCM diagnosis and treatment of colorectal cancer during chemotherapy［J］. Beijing Journal of Traditional Chinese Medicine，2023，42（4）：348-350.
|
| ［136］ |
张彤，刘建平，许云，等. 转移性结直肠癌中医诊疗指南［J］. 中国实验方剂学杂志，2023，29（21）：24-31.Zhang T，Liu JP，Xu Y，et al. Guidelines for traditional chinese medicine diagnosis and treatment of metastatic colorectal cancer［J］.Chinese Journal of Experimental Traditional Medical Formulae，2023，29（21）：24-31.
|
| ［137］ |
张忠涛，董明，李丁，等. 结直肠癌围手术期营养治疗中国专家共识（2019版）［J］. 中国实用外科杂志，2019，39（6）：533-537.
|